AlphAIAlphAI — Financial news for AI agents
tradingview.comNOV 31 min read$CORT

Corcept Therapeutics Incorporated (CORT) Q3 Revenue Reached $340.5M

Corcept Therapeutics reported Q3 2026 revenue of $340.5M, up from $256.1M in Q2, with net income rising to $126.8M from $43.0M. The company maintained its 2026 revenue guidance of $1.1B–$1.2B. Growth was driven by its oncology business, with upcoming data from BELLA, TRIDENT, and SYNERGY trials expected in 2027.

Original reporting
tradingview.com
Published Nov 3, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Corcept Therapeutics Incorporated (CORT) Q3 Revenue Reached $340.5M — source image
Source · tradingview.com
Decision brief

The 30-second read

$CORTBullishHigh
01

Why it matters

The earnings beat may drive short‑term buying pressure, while the unchanged guidance keeps longer‑term expectations stable.

02

Market read

First‑report earnings for a mid‑cap biotech; relevant for sector traders and earnings‑focused investors.

03

What to watch

Potential upcoming trial results for BELLA, TRIDENT and SYNERGY could add volatility.

Relevance 8/10Novelty 8/10Timing: post‑release today

Background

Corcept Therapeutics released its Q3 2026 earnings, showing sequential growth and reaffirming full‑year revenue guidance.

Company-level read

Ticker impact

$CORTBullishHigh confidence
Context

Q3 2026 revenue rose to $340.5M and net income to $126.8M, beating prior quarter and reaffirming 2026 guidance.

Expected impact

potential upside as market prices in the earnings beat and reaffirmed guidance

Evidence & confidence

Revenue and profit both increased significantly quarter‑over‑quarter and guidance remains unchanged, indicating continued momentum.

Market effects

Sector

Biotech sector may see modest rally on strong earnings from a peer.

Regional

US biotech stocks could gain on the positive surprise.

Global

Limited to investors tracking US biotech earnings.

Counterpoint

What could challenge this read

If guidance is unchanged despite higher revenue, investors may question future growth sustainability.

Key entities

  • company
    Corcept Therapeutics Incorporated

    Biopharma focused on endocrine disorders.

Read at source← All news

StoryCorcept Therapeutics posts Q3 earnings beat, keeps 2026 revenue guidance and awaits FDA decision

Also covered by

3 outlets

Related articles

NOV 4
$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.

finance.yahoo.com3 min
NOV 3
$CORTHighAI 8/10

Corcept’s (NASDAQ:CORT) Q3 2026: beats on revenue

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $340.5M, up 64% YoY and 1.9% above estimates. EPS of $1.01 beat estimates by 27.2%. The company reconfirmed its full-year revenue guidance of $1.15B. Operating margin improved to 33.7% YoY. CEO highlights growth in endocrinology and ovarian cancer treatments.

finance.yahoo.com2 min
NOV 3
$CORTMed

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

CORCEPT THERAPEUTICS INC (CORT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update • Revenue of $340.5 million, a 64 percent increase over the same period in 2025 ◦ Korlym ® and authorized generic product revenue of $249.1 million ◦ Lifyorli ® product reven

SEC EDGAR 8-K2 min